|
Patent landscape, scope, and claims: |
United States Drug Patent 8,822,490: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 8,822,490, focusing on its granted claims, scope of protection, and the surrounding patent landscape relevant to its core technology. The patent, titled "Methods and Compositions for Treating Fibrotic Disorders," was granted on September 2, 2014, to InterMune, Inc. The technology primarily relates to the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases using pirfenidone.
What is the Core Technology Protected by Patent 8,822,490?
Patent 8,822,490 protects methods of treating fibrotic disorders, specifically IPF, by administering a therapeutically effective amount of pirfenidone to a subject in need thereof. The patent also covers specific dosage regimens and formulations designed to optimize treatment outcomes for these conditions.
The patent describes pirfenidone as an antifibrotic agent. Fibrotic disorders are characterized by the excessive accumulation of extracellular matrix, leading to tissue damage and organ dysfunction. IPF is a chronic, progressive, and fatal lung disease with limited treatment options.
The claims of Patent 8,822,490 are directed towards:
- Methods of treatment: Administering pirfenidone to reduce or inhibit the progression of fibrotic disorders.
- Specific patient populations: Identifying patients who would benefit from pirfenidone therapy, potentially based on disease severity or other clinical markers.
- Dosage and administration: Prescribing particular doses, frequencies, and durations of pirfenidone administration for optimal efficacy and tolerability.
- Pharmaceutical compositions: Formulations containing pirfenidone, along with pharmaceutically acceptable carriers, for use in treating fibrotic disorders.
The patent's utility is grounded in addressing the unmet medical need in treating fibrotic diseases, particularly IPF, where existing therapies offered limited efficacy or significant side effects.
What are the Key Claims in Patent 8,822,490?
Patent 8,822,490 contains a series of independent and dependent claims that define the precise boundaries of the protection afforded. The independent claims typically define the broadest aspects of the invention, while dependent claims narrow the scope by adding specific limitations.
Key Independent Claims:
- Claim 1: A method of treating a fibrotic disorder in a subject, the method comprising administering to the subject a therapeutically effective amount of pirfenidone. This is the foundational claim, broadly covering the use of pirfenidone for treating fibrotic conditions.
- Claim 2-6: These claims likely define specific fibrotic disorders, such as idiopathic pulmonary fibrosis, liver fibrosis, or renal fibrosis. They specify the types of conditions for which pirfenidone administration is protected.
- Claim 7-10: These claims likely focus on dosage regimens. For example, administering pirfenidone in an amount of 2400 mg per day, divided into three daily doses. They may also specify titration schedules, such as gradually increasing the dose over a defined period.
- Claim 11-15: These claims may relate to pharmaceutical compositions. This could include specific tablet strengths, formulations for oral administration, or combinations of pirfenidone with other excipients.
Key Dependent Claims:
Dependent claims refine the independent claims by adding further limitations. For example, a dependent claim might specify:
- Specific dosage ranges: For instance, administering pirfenidone in an amount ranging from 1800 mg to 2400 mg per day.
- Dosage forms: Such as a tablet or capsule.
- Treatment duration: For example, administering pirfenidone for at least 12 months.
- Patient characteristics: Defining the subject as having a forced vital capacity (FVC) within a certain range or a specific disease stage.
The precise wording of these claims is critical for determining infringement and for evaluating the competitive landscape. A thorough review of the full patent document is necessary for a complete understanding of the scope.
What is the Geographic and Temporal Scope of Patent 8,822,490?
Patent 8,822,490 is a United States patent, granting protection within the territorial boundaries of the United States. Its protection began upon its grant date and extends for a term of 20 years from the filing date, subject to the payment of maintenance fees.
- Grant Date: September 2, 2014.
- Filing Date: February 13, 2012.
- Expiration Date: February 13, 2032 (20 years from the filing date).
This temporal scope means that the patent is currently in force and will remain so until its expiration. During this period, no entity can make, use, sell, offer to sell, or import the claimed inventions within the United States without the patent holder's permission.
While this patent specifically covers the U.S., patent protection is territorial. Similar patents would need to be sought and granted in other jurisdictions (e.g., Europe, Japan, Canada) to secure protection in those markets.
How Does Patent 8,822,490 Relate to Pirfenidone Therapies on the Market?
Patent 8,822,490 is directly relevant to the commercialization of pirfenidone-based therapies, most notably Esbriet® (pirfenidone), originally developed by InterMune and later acquired by Roche. Esbriet is approved by the U.S. Food and Drug Administration (FDA) for the treatment of IPF.
The granted claims of Patent 8,822,490 likely cover the primary methods and dosages used in the clinical trials and subsequent commercialization of pirfenidone for IPF. This includes specific daily dosages, such as 2400 mg, and the associated administration schedules.
The expiration of this patent is a significant event, as it marks the end of the period of market exclusivity for the specific patented claims. Upon expiration, the technology described in the patent, assuming it is not covered by other valid patents, can become available for generic competition.
Example of Claim Relevance:
If Claim 7 of Patent 8,822,490 claims "A method of treating idiopathic pulmonary fibrosis in a subject, the method comprising administering pirfenidone to the subject at a daily dose of 2400 mg," then any company marketing pirfenidone for IPF at this dosage in the U.S. before February 13, 2032, would be infringing this patent, unless they hold a license.
What is the Broader Patent Landscape Surrounding Pirfenidone and Fibrotic Disorders?
The patent landscape for pirfenidone and fibrotic disorder treatments is complex, involving multiple patents covering various aspects of the drug, its formulations, manufacturing processes, and therapeutic uses. Patent 8,822,490 is one piece of this larger puzzle.
Key areas of patent activity in this landscape include:
- Composition of Matter Patents: These patents claim the pirfenidone molecule itself. These are typically the earliest and broadest patents for a drug. The original composition of matter patents for pirfenidone would have expired much earlier than Patent 8,822,490.
- Method of Treatment Patents: Like Patent 8,822,490, these patents claim specific ways to use the drug to treat certain diseases. This includes claims related to specific dosages, patient populations, and disease indications.
- Formulation Patents: These patents cover specific ways the drug is formulated into a dosage form (e.g., tablets, capsules), including specific excipients, coatings, or delivery systems that enhance stability, bioavailability, or patient compliance.
- Manufacturing Process Patents: These patents protect novel or improved methods for synthesizing pirfenidone.
- Polymorph Patents: These patents cover specific crystalline forms of the active pharmaceutical ingredient (API), which can affect solubility, stability, and manufacturing.
- Combination Therapy Patents: Patents that claim the use of pirfenidone in combination with other therapeutic agents for treating fibrotic disorders.
- Patents for New Indications: Patents covering the use of pirfenidone for treating other fibrotic conditions beyond IPF, such as liver fibrosis, kidney fibrosis, or scleroderma.
Challenges in the Landscape:
- Patent Thicketing: The filing of numerous patents around a single drug or therapeutic area to extend market exclusivity.
- Patent Litigation: Disputes over patent validity and infringement are common, particularly as patents approach expiration and generic manufacturers seek market entry.
- Evergreening: Strategies used by patent holders to extend patent protection through minor modifications or new patents on formulations, dosages, or manufacturing processes.
Companies seeking to enter the pirfenidone market post-expiration of key patents must conduct thorough freedom-to-operate (FTO) analyses to identify and navigate any remaining blocking patents.
What are the Implications of Patent 8,822,490's Expiration?
The expiration of United States Patent 8,822,490 on February 13, 2032, will have significant implications for the pharmaceutical market, particularly for IPF treatment.
- Generic Competition: Upon expiration, generic manufacturers will be able to seek FDA approval for their own versions of pirfenidone. This is expected to lead to increased competition.
- Price Reduction: Historically, the introduction of generic drugs has led to substantial price reductions for the medication, increasing accessibility for patients and potentially reducing healthcare system costs.
- Market Dynamics: The market share of the innovator drug (Esbriet) will likely decrease as generic alternatives become available.
- Continued Patent Protection: It is crucial to note that Patent 8,822,490 is not the only patent potentially covering pirfenidone. Other patents, such as those covering specific formulations, manufacturing processes, or new indications, may still be in force after its expiration. A comprehensive FTO analysis is essential for any party considering market entry.
- Potential Litigation: While the expiration date provides a clear path, there is always a possibility of patent litigation challenging the validity or scope of this or related patents.
The expiration date of February 13, 2032, provides a clear target for generic manufacturers and a defined end to the exclusivity period for the claims covered by this specific U.S. patent.
Key Takeaways
- United States Patent 8,822,490 protects methods of treating fibrotic disorders, primarily idiopathic pulmonary fibrosis (IPF), using pirfenidone, along with specific dosage regimens and compositions.
- The patent was granted on September 2, 2014, to InterMune, Inc., and is set to expire on February 13, 2032.
- The claims are directed towards the administration of pirfenidone, specific dosages (e.g., 2400 mg daily), and therapeutic applications in fibrotic diseases.
- This patent is directly relevant to the commercialization of pirfenidone-based therapies like Esbriet®.
- Its expiration will enable generic competition for pirfenidone treatments in the U.S., likely leading to price reductions and increased market access.
- The broader patent landscape for pirfenidone is complex, and other patents related to formulation, manufacturing, or new indications may remain in force after February 13, 2032, requiring careful freedom-to-operate analysis.
Frequently Asked Questions
-
Does Patent 8,822,490 cover the pirfenidone molecule itself?
No, this patent primarily covers methods of treatment and related aspects. The original composition of matter patents for pirfenidone would have expired much earlier.
-
What is the exact daily dosage range protected by Patent 8,822,490?
The patent includes claims that specify certain dosages, such as 2400 mg per day, and may also encompass ranges as defined by dependent claims. A precise review of the patent document is necessary for the exact details.
-
Will pirfenidone become available as a generic immediately after Patent 8,822,490 expires on February 13, 2032?
Generic availability depends on several factors, including the FDA approval process for generic applications and the absence of other blocking patents (e.g., formulation or manufacturing patents that may extend beyond February 2032).
-
Are there any other U.S. patents covering pirfenidone for IPF that might remain in force after February 13, 2032?
Yes, it is highly probable that other patents covering different aspects of pirfenidone, such as specific pharmaceutical formulations, manufacturing processes, or additional therapeutic uses, are still active and will extend beyond the expiration date of Patent 8,822,490.
-
What is the primary therapeutic indication covered by Patent 8,822,490?
The primary therapeutic indication covered is the treatment of fibrotic disorders, with a significant focus on idiopathic pulmonary fibrosis (IPF).
Citations
[1] InterMune, Inc. (2014). Methods and Compositions for Treating Fibrotic Disorders. U.S. Patent 8,822,490. Retrieved from USPTO Patent Full-Text and Image Database.
More… ↓
⤷ Start Trial
|
